Physician profile
John Judd Friedewald
NPI 1508801093
$93,168.69
in general payments reported to CMS, 2019-2025
17 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,349 · 2020: $9,902 · 2021: $5,387 · 2022: $13K · 2023: $15K · 2024: $30K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $14K · Travel and Lodging: $4,666 · Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,369.00 |
| Consulting Fee | $14,110.00 |
| Travel and Lodging | $4,665.94 |
| Food and Beverage | $1,959.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $56,245.83 | 2021-2025 | |
| Veloxis Pharmaceuticals, INC. | $8,938.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $7,310.00 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $6,881.75 | 2024 | Uvadex, Terlivaz |
| Genzyme Corporation | $6,329.00 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $5,081.22 | 2025 | |
| One Lambda, INC. | $2,049.19 | 2025 | |
| Alexion Pharmaceuticals, INC. | $184.95 | 2021-2025 | Ultomiris |
| Amgen INC. | $55.08 | 2022 | |
| Akebia Therapeutics INC | $40.00 | 2019 | |
| Gilead Sciences, INC. | $30.91 | 2024 | |
| Eurofins Viracor, LLC | $22.44 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Friedewald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.